Clinical Trial

Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 22, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will be evaluating safety and efficacy of the combination of lenvatinib and pembolizumab neoaadjuvant therapy prior to surgical resection of locally advanced renal cell carcinoma with IVC tumor thrombus.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2022-03-31; most recent amendment 2025-08-20.
Status change: Not Yet Recruiting → Recruiting 2023-02-06
Trial Details
NCT Number NCT05319015
Lead Sponsor University of Texas Southwestern Medical Center
Conditions Renal Cell Carcinoma
Enrollment 30 participants
Start Date 2023-01-06
Primary Completion 2026-07 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2025-08-22